Yuki Yoshikawa

Integrated Analysis of HER2 Expression and ERBB2 Alterations in Bladder Cancer

ABSTRACT Human epidermal growth factor receptor 2 (HER2) has emerged as a potential therapeutic target in bladder cancer (BC), particularly with the advent of next‐generation antibody–drug conjugates (ADCs) like trastuzumab deruxtecan (T‐DXd). However, the complex relationship be...